Advertisement
News
Advertisement

LuViva demonstration unit shipped to U.K. distributor

Wed, 04/18/2012 - 4:45am
The Associated Press

GATESHEAD, United Kingdom--(BUSINESS WIRE)--Apr 18, 2012-- Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the LuViva(R) Advanced Cervical Scan is being introduced to medical thought leaders at the 40th Anniversary Meeting of the British Society for Colposcopy and Cervical Pathology (BSCCP) in Gateshead, U.K. by Eurosurgical Ltd, the company's U.K. distributor. The meeting runs from April 18th to 20th.

In the United Kingdom, LuViva is initially intended as a follow-up test after a positive Pap test. Today in the U.K., approximately 400,000 women annually are referred to more than 170 institutions for a follow-up or colposcopy examination, which often involves a biopsy of the cervix. Based on its clinical trial results, LuViva could eliminate approximately 40 percent of unnecessary follow-up procedures and could identify serious cervical disease up to two years earlier than the standard of care.

"The BSCCP meeting is an important gathering of leading women's healthcare providers from across the UK and Ireland and an excellent venue to introduce LuViva ahead of its anticipated launch later this year," said Mark L. Faupel, Ph.D., CEO and president of Guided Therapeutics, Inc.

Eurosurgical purchased, and recently received, the first LuViva demonstration unit shipped to the European Union. Demonstration units are designed to educate the sales force and show the functionality of the product to medical professionals. The company anticipates CE mark approval in the second quarter of 2012.

"Eurosurgical is pleased to be at the forefront of improving women's healthcare through new and innovative technologies like LuViva," said Peter Parker, Managing Director of Eurosurgical Ltd.

About the BSCCP BSCCP, founded in 1972, represents a common forum for the discussion and debate of all matters pertaining to the prevention of cancer of the cervix. By its very nature the Society is multidisciplinary, a fact that almost certainly explains its strengths and continued growth. Most, if not all, members find membership, and particularly attendance at the Annual Scientific Meeting, a major influence in their practice and a key feature of their postgraduate education.

Change affects all branches of healthcare and cervical disease is no exception. The balance between basic science, epidemiology, clinical care and service/patient interface is a characteristic of the Society and is typified by the high standard and variety of papers presented at the Annual Scientific Meeting. Eurosurgical Ltd will be exhibiting at stands 10 and 11 on Level One.

About Eurosurgical Eurosurgical Ltd was founded in 1988 to specialise in the sales and marketing of surgical equipment, instruments and devices to the medical profession in disciplines such as Gynaecology & Obstetrics, Plastic Surgery, Cosmetic & Reconstructive Surgery, General Surgery and Minimally Invasive Surgery (M.I.S).

Eurosurgical Ltd is committed to the supply of medical devices to achieve customer satisfaction and, in doing so, maintain business profitability and encourage further business expansion. The company aims to involve its workforce, customers and suppliers in a continual process of feedback and improvement such that its responsiveness and effectiveness to its customers' requirements and expectations are monitored and, where necessary, improved. For more information visit www.eurosurgical.co.uk.

Eurosurgical Ltd is also a member of the European Medical Device Distributors Alliance (EMDDA), a network of European medical device distributors formed in 1993 to benefit from each member's strengths and to share information about the European medical device market.

About LuViva (R) Advanced Cervical Scan LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which eliminates costly, painful and unnecessary testing. LuViva is designed for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. The device is used in conjunction with the LuViva(R) Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level. The Company's first planned product is the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. Guided Therapeutics has also entered into a partnership with Konica Minolta Opto to develop a non-invasive test for Barrett's Esophagus using the technology platform. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva (R) Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include: the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and subsequent quarterly reports.

CONTACT: Cameron Associates Investors: Alison Ziegler, 212-554-5469 or Guided Therapeutics Bill Wells, 770-242-8723 Ext. 241 KEYWORD: UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA GEORGIA INDUSTRY KEYWORD: WOMEN HEALTH MEDICAL DEVICES ONCOLOGY CONSUMER SOURCE: Guided Therapeutics, Inc.

Copyright Business Wire 2012 PUB: 04/18/2012 08:05 AM/DISC: 04/18/2012 08:05 AM http://www.businesswire.com/news/home/20120418005185/

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading